GlassScriptPhysician profile
Lyle Zepick
NPI 1346294808
$4,061.05
in general payments reported to CMS, 2019-2025
32 companies · $825 in 2025
The $825 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $238 · 2021: $448 · 2022: $469 · 2023: $268 · 2024: $890 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.53 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $470.30 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $350.25 | 2020-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.53 | 2020-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $308.01 | 2021-2025 | Verquvo |
| Astellas Pharma US INC | $295.01 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $241.25 | 2021-2025 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $237.74 | 2019-2022 | |
| Medtronic, INC. | $232.69 | 2021-2024 | Micra |
| Astrazeneca Pharmaceuticals LP | $224.22 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $223.12 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $222.54 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $191.64 | 2022 | |
| Abbott Laboratories | $98.92 | 2020-2025 | Merlin@Home, Jot Dx, Gallant |
| Amarin Pharma, INC. | $68.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $57.23 | 2020-2024 | Xarelto |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $55.77 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $51.27 | 2023-2024 | Inpefa |
| Pfizer INC. | $46.81 | 2019-2025 | |
| Medtronic Vascular, INC. | $44.55 | 2019-2020 | |
| Boston Scientific Corporation | $42.66 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $38.38 | 2023 | Arcalyst |
| Philips North America LLC | $37.84 | 2025 | Extended Holter |
| Abiomed | $34.73 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.17 | 2022 | |
| United Therapeutics Corporation | $23.45 | 2025 | Orenitram, Remodulin |
| Inspire Medical Systems, INC. | $23.18 | 2024 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $21.75 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $18.56 | 2025 | Assure Wcd |
| Amryt Pharma Holdings LTD | $15.53 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.75 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $12.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyle Zepick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.